THE HON MARK BUTLER MP
Minister for Mental Health and Ageing
Minister for Social Inclusion
Minister Assisting the Prime Minister on Mental Health Reform
Health and medical research into dementia, macular degeneration and other age-related conditions will benefit from $50 million in new Australian Government funding.
Minister for Mental Health and Ageing Mark Butler today announced funding for 92 National Health and Medical Research Council (NHMRC) grants.
“The potential of the projects to help us gain a better understand the management of osteoarthritis, and give us more information on the relationship between iron deposits in the brain and Parkinson’s and Alzheimer’s disease for example, is very exciting.”
“The Australian Government is committed to improving the health and quality of life of our older Australians.”
“One of the key ways we can achieve these goals is by funding quality research that will expand our knowledge of the diseases that affect our elderly population,” Mr Butler said.
The NHMRC grant allocations include:
- 46 ageing grants totalling $28,152,874
- 29 dementia grants totalling $13,247,849
- 17 Parkinson's disease grants totalling $8,630,990.
Grant highlights include:
- Dr Ashley Bush, University of Melbourne, will receive $807,822 to look at the relationship between the regulation of iron levels in the brain and the development of dementia.
- Dr Arthur Thevathasan, University of Melbourne, will receive $215,738 to develop a new treatment for gait ‘freezing’ and poor balance associated with Parkinson’s disease. The treatment involves implanting a pacemaker into a very deep brain region.
- Professor Perminder Sachdev of the University of New South Wales will receive $912,023 for the Older Australian Twins Study (OATS) of healthy brain ageing and age-related neurocognitive disorders.
- Doctor Joseph Nicolazzo of Monash University will receive $281,456 for a study which looks at a novel approach for the treatment of Alzheimer’s disease.
- Professor Andreas Evdokiou of The University of Adelaide will receive $455,695 to look at a new therapeutic approach targeting pathological bone loss associated with osteoporosis.